Twist Bioscience Enters into Multiple Agreement with Astellas to Identify Antibodies & Reduce Tumor Microenvironment-Mediated Immunosuppression
Shots:
- Twist to receive an up front & additional fees upon licensing option & is eligible to receive success-based clinical milestones along with royalty on product sales for each licensed product. Additionally, both companies will jointly conduct research activities to identify & optimize Twist antagonist Abs targeting checkpoint inhibitor pathway in TME
- Astellas to get an exclusive option to license developed products that emerge from the collaboration & will be responsible to develop, manufacturing & commercialize licensed products
- The agreement will use Twist’ Ab discovery & optimization capabilities & Astellas' flexible convertible CAR cell therapy technology to discover next-generation therapies
Ref: Businesswire | Image: Astellas
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
